The News Review:
- NovaBay Pharmaceuticals Inc. Reports First Quarter 2009 Financial …
- Quotient Bioresearch Acquires Edinburgh Clinical Research Facility …
- News Feed Item
NovaBay Pharmaceuticals Inc. Reports First Quarter 2009 Financial …
PR Newswire (press release)
9 million up from $12. 1 million at December 31 2008. The increase was largely due to receipt of milestone payments from Alcon and upfront payments from Galderma as well as reduced spending on overhead and delayed research and development costs. “We believe the first quarter of 2009 was one of continued accomplishment for NovaBay as we achieved business development and clinical progress in advancing our first-in-class Aganocide(R) compounds that are designed to mimic the human body’s natural defense against infection without developing resistance” said Dr. Ron Najafi chairman and chief executive officer of NovaBay. “ur collaboration with Galderma for the Aganocides in major dermatological conditions further validates the potential for our novel potent anti-infectives. At the same time our pipeline continued to advance during the quarter and we recently announced an agreement with Professors Nagl and Gottardi of Medical University of Innsbruck – Austria pioneers in the clinical evaluation of the endogenous unstable molecule upon which NovaBay’s proprietary Aganocides are based to broaden our intellectual property portfolio and expand the clinical opportunities for the Aganocides.
Related from Affiliaterevenuemonster: BMP Sunstone Reports First Quarter 2009 Financial Results
Quotient Bioresearch Acquires Edinburgh Clinical Research Facility …
RealWire (press release)
This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility formerly Inveresk Clinical Research will combine with Pharmaceutical Profiles acquired by Quotient in December 2008 to form a new strategic business unit within Quotient – Quotient Clinical. With a long heritage in early development services the Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles to offer a suite of integrated services stretching from First-in-Human (FIH) through to Phase 2a patient studies. Founded almost 20 years ago the Edinburgh clinical unit is an industry leader in FIH studies. It was awarded Supplementary Accreditation status by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2009 demonstrating its experience and capabilities to conduct FIH trials for small molecules and biologics. Quotient Clinical will have a workforce of approximately 160 medical scientific and clinical staff across the two facilities in Edinburgh and Nottingham.
News Feed Item
SYS-CN Media (press release)
Their tests have shown advantages in cost speed and accuracy compared with conventional biochemical testing and gene sequencing methods routinely used in their lab. The collaboration with the NIH group is currently focused on expanding the database for identification of mycobacteria nocardia and filamentous yeasts. In addition larger scale clinical research studies are also underway at the microbiology departments of two major U. medical school hospitals and results from those studies are expected in 2009. CI CT & Developer Resources.
